Health-related quality of life of long-term patients receiving opioid agonist therapy: a nested prospective cohort study in Norway
-
Published:2020-09-03
Issue:1
Volume:15
Page:
-
ISSN:1747-597X
-
Container-title:Substance Abuse Treatment, Prevention, and Policy
-
language:en
-
Short-container-title:Subst Abuse Treat Prev Policy
Author:
Aas Christer FrodeORCID, Vold Jørn Henrik, Skurtveit Svetlana, Lim Aaron G., Ruths Sabine, Islam Kamrul, Askildsen Jan Erik, Løberg Else-Marie, Fadnes Lars Thore, Johansson Kjell Arne, Aas Christer Frode, Buljovcic Vibeke Bråthen, Chalabianloo Fatemeh, Daltveit Jan Tore, Alpers Silvia Eiken, Fadnes Lars T., Eriksen Trude Fondenes, Gundersen Per, Hille Velinda, Håberg Kristin Holmelid, Johansson Kjell Arne, Leiva Rafael Alexander, Carlsen Siv-Elin Leirvåg, Bonnier Martine Lepsøy, Lorås Lennart, Løberg Else-Marie, Nordbotn Mette Hegland, Nygård Cathrine, Olsvold Maria, Ohldieck Christian, Sivertsen Lillian, Torjussen Hugo, Vold Jørn Henrik, Økland Jan-Magnus, Eielsen Tone Lise, Maldonado Nancy Laura Ortega, Wilk Ewa Joanna, Bjørnestad Ronny, Lygren Ole Jørgen, Pierron Marianne Cook, Dalgard Olav, Midgard Håvard, Skurtveit Svetlana, Vickerman Peter,
Abstract
Abstract
Background
Opioid dependence carries the highest disease burden of all illicit drugs. Opioid agonist therapy (OAT) is an evidence-based medical intervention that reduces morbidity and mortality. There is limited knowledge on the health-related quality of life (HRQoL) of long-term patients in OAT. This study measures HRQoL and self-perceived health of long-term patients on OAT, compares the scores to a Norwegian reference population, and assesses changes in these scores at 1-year follow up.
Methods
We conducted a nested prospective cohort study among nine OAT outpatient clinics in Norway. 609 OAT patients were included, 245 (40%) followed-up one year later. Data on patient characteristics, HRQoL, and self-perceived health was collected. HRQoL was assessed with the EQ-5D-5L, which measures five dimensions (mobility, self-care, usual activities, pain/discomfort and anxiety/depression) on a five-point Likert scale (from “no problems” to “extreme problems”). An UK value set was applied to calculate index values (from 0 to 1) for the EQ-5D-5L and compare them to a Norwegian reference population. Self-perceived health was measured with EQ-VAS (from 0 to 100).
Results
Mean (standard deviation (SD)) EQ-5D-5L index value at baseline was 0.699 (0.250) and EQ-VAS 57 (22) compared to 0.848 (0.200) and 80(19) for the Norwegian reference population. There were large variations in EQ-5D-5L index values, where 43% had > 0.8 and 5% had < 0.2 at baseline. The lowest EQ-5D-5L index values were observed for female patients, age groups older than 40 years and for methadone users. At follow-up, improvements in HRQoL were observed across almost all dimensions and found significant for mobility and pain/discomfort. Mean (SD) overall index value and EQ-VAS at follow up were 0.729 (0.237) and 59 (22) respectively.
Conclusion
The average HRQoL and self-perceived health of OAT patients is significantly lower than that of the general population, and lower than what has been found among other severe somatic and psychiatric conditions. Around 34% had very good HRQoL, higher than average Norwegian values, and around 5% had extremely poor HRQoL.
Funder
Norges Forskningsråd Helse Vest
Publisher
Springer Science and Business Media LLC
Subject
Psychiatry and Mental health,Health Policy
Reference54 articles.
1. World Health Organization. Management of substance abuse: Dependence syndrome, ICD-10 Clinical description; 2020. https://www.who.int/substance_abuse/terminology/definition1/en/. 2. Chang HY, Kharrazi H, Bodycombe D, Weiner JP, Alexander GC. Healthcare costs and utilization associated with high-risk prescription opioid use: a retrospective cohort study. BMC Med. 2018;16(1):69. 3. Degenhardt L, Grebely J, Stone J, Hickman M, Vickerman P, Marshall BDL, Bruneau J, Altice FL, Henderson G, Rahimi-Movaghar A, et al. Global patterns of opioid use and dependence: harms to populations, interventions, and future action. Lancet (London, England). 2019;394(10208):1560–79. 4. Gomes T, Tadrous M, Mamdani MM, Paterson JM, Juurlink DN. The burden of opioid-related mortality in the United States. JAMA Netw Open. 2018;1(2):e180217. 5. European Monitoring Centre for Drugs and Drug Addiction: European Drug Report. Trends and Developments. In.; 2019.
Cited by
28 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
|
|